ClinicalTrials.gg
CompletedNCT00462670Updated Feb 4, 2014Results posted

A Double-blind, Placebo-controlled Study of OPC-41061 in the Treatment of Cardiac Edema (Congestive Heart Failure)

A Phase 3 interventional study of OPC-41061(Tolvaptan) in Edema, Cardiac, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 8 sites in Japan. Open to participants aged 20 Years to 85 Years. Per ClinicalTrials.gov, last updated 2014-02-04.

Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
20 Years to 85 Years
Sex
All
01

Study summary

To evaluate the efficacy and safety of 7-day repeated oral administration of OPC-41061 15 mg or placebo in congestive heart failure (CHF) patients with extracellular volume expansion despite the use of a conventional diuretic.

02

Conditions studied

  • Edema, Cardiac

Keywords

  • Cardiac edema
  • OPC-41061
  • Vasopressin antagonist
03

In context

Lead sponsor

Otsuka Pharmaceutical Co., Ltd. is the lead sponsor of 143 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects receiving one of the following diuretic treatments (including subjects scheduled to start treatment during the run-in observation period, 1)A loop diuretic at a daily dosage equivalent to 40 mg or more of furosemide, 2)Concomitant administration of a loop diuretic and a thiazide diuretic (at any doses), 3)Concomitant administration of a loop diuretic and an anti-aldosterone drug (at any doses)
  2. CHF patients with lower limb edema, jugular venous distention, or pulmonary congestion due to extracellular volume expansion Patients with pulmonary congestion can be enrolled if pulmonary congestion is confirmed on chest x-ray taken within 14 days prior to the screening examination.
  3. Male or female subjects age 20 or older and younger than 85 (at time of )
  4. Subjects who are able to stay at the study site from the day before the start of the run-in observation period until completion of postdosing examination 2 (7 to 10 days after final study drug administration)
  5. Subjects capable of giving informed consent to participate in the study of their own free will

Exclusion criteria

Exclusion Criteria:

  1. Subjects with acute heart failure
  2. Subjects with an assisted circulation device
  3. Subjects with any of the following complications or symptoms: (1)Suspected decrease in circulatory blood flow, (2)Hypertrophic cardiomyopathy (other than dilated phase), (3)Cardiac valve disease with significant heart valve stenosis, (4)Hepatic coma
  4. Subjects who develop acute myocardial infarction within 30 days prior to the screening examination
  5. Subjects with a definite diagnosis of active myocarditis or amyloid cardiomyopathy
  6. Subjects with any of the following complications or symptoms: (1)Diabetes mellitus with poorly controlled blood glucose, (2)Anuria, (3)Urination impaired due to urinary tract stricture, urinary calculus, tumor in urinary tract, or other cause
  7. Subjects with a history of any of the following diseases: (1)Sustained ventricular tachycardia or ventricular fibrillation within 30 days prior to the screening examination in patients without an implanted defibrillator, (2)Cerebrovascular disorder within 6 months prior to the screening examination (other than asymptomatic cerebral infarction), (3) or idiosyncratic reaction to benzazepine derivatives such as mozavaptan hydrochloride or benazepril hydrochloride.
  8. Subjects who are obese [ (BMI, body weight (kg)/height (m)2 exceeding 35]
  9. Patients with supine systolic blood pressure exceeding 90 mmHg
  10. Subjects with any of following abnormal laboratory values: (1)Total exceeding 3.0 mg/dL, (2)serum creatinine exceeding 3.0 mg/dL, (3)serum sodium exceeding 147 mEq/L, (4)serum potassium exceeding 5.5 mEq/L
  11. Patients who are unable to take oral medication
  12. Female subjects who are pregnant, possibly pregnant, or lactating, or who plan to become pregnant
  13. Subjects who received any drug other than OPC-41061 within 30 days prior to the screening examination
  14. Subjects who previously participated in this or any other study of OPC-41061 and received OPC-41061
  15. Subjects otherwise judged by the investigator or subinvestigator to be inappropriate for inclusion in the study
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
110 participants (actual)

Study arms

  • Placebo comparator
    1

    0mg

    Drug: OPC-41061(Tolvaptan)

  • Experimental
    2

    15mg OPC-41061

    Drug: OPC-41061(Tolvaptan)

Interventions

06

What researchers measure

Primary outcomes

  1. Body Weight (Amount of Change)

    Change in body weight from baseline at the time of final trial drug administration

    Time frame: baseline, Day 7 or at the time of final trial drug administration

Secondary outcomes

  1. Body Weight (Percent Change)

    Percent change in body weight from baseline at the time of final trial drug administration

    Time frame: baseline, Day 7 or at the time of final trial drug administration

07

Results

Posted Feb 4, 2014

Participant flow

Participant flow — Overall Study
MilestonePlaceboOPC-41061 15mg
Started5753
Completed5246
Not completed57
Withdrew: Adverse event35
Withdrew: Lack of efficacy10
Withdrew: Protocol violation10
Withdrew: Resolution of signs and symptoms02

Outcome measures

PrimaryBody Weight (Amount of Change)

Change in body weight from baseline at the time of final trial drug administration

Time frame:
baseline, Day 7 or at the time of final trial drug administration
Reported as:
Mean · Kg
Body Weight (Amount of Change)
KgPlaceboOPC-41061 15mg
Body Weight (Amount of Change)-0.45 ± 0.93-1.54 ± 1.61
Statistical analysis
  • Placebo vs OPC-41061 15mg · t-test, 2 sided · p = <0.0001 · Mean difference (final values): -1.09 · 95% CI -1.58 to -0.60
SecondaryBody Weight (Percent Change)

Percent change in body weight from baseline at the time of final trial drug administration

Time frame:
baseline, Day 7 or at the time of final trial drug administration
Reported as:
Mean · percentage of body weight (Kg)
Body Weight (Percent Change)
percentage of body weight (Kg)PlaceboOPC-41061 15mg
Body Weight (Percent Change)-0.77 ± 1.65-2.50 ± 2.55
Statistical analysis
  • Placebo vs OPC-41061 15mg · t-test, 2 sided · p = <0.0001 · Mean difference (final values): -1.73 · 95% CI -2.54 to -0.92

Adverse events

Collected over 7 days. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—7/57 (12.3%)31/57 (54.4%)
OPC-41061 15mg—2/53 (3.8%)28/53 (52.8%)
Most frequent serious events
Most frequent serious events
EventPlaceboOPC-41061 15mg
Cardiac FailureCardiac disorders2/571/53
Atrial FibrillationCardiac disorders0/571/53
Renal failure chronicRenal and urinary disorders0/571/53
Ventricular TachycardiaCardiac disorders1/570/53
PyrexiaGeneral disorders1/570/53
Femoral neck fractureInjury, poisoning and procedural complications1/570/53
HyperkalaemiaMetabolism and nutrition disorders1/570/53
Cerebral infarctionNervous system disorders1/570/53
Most frequent other events
Showing 10 of 20
Most frequent other events
EventPlaceboOPC-41061 15mg
Blood Urea IncreasedInvestigations10/575/53
ConstipationGastrointestinal disorders3/579/53
ThirstGeneral disorders1/579/53
Blood Creatinine IncreasedInvestigations7/574/53
PollakiuriaRenal and urinary disorders0/575/53
Blood Potassium IncreasedInvestigations4/573/53
NauseaGastrointestinal disorders0/573/53
MalaiseGeneral disorders0/573/53
Blood Uric Acid IncreasedInvestigations3/573/53
NasopharyngitisInfections and infestations3/571/53

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)PlaceboOPC-41061Total
<=18 years000
Between 18 and 65 years191231
>=65 years384179
Age, Continuous
Age, Continuous(years)PlaceboOPC-41061Total
Mean71.0 ± 10.971.3 ± 10.671.2 ± 10.7
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboOPC-41061Total
Female181836
Male393574
Region of Enrollment
Region of Enrollment(participants)PlaceboOPC-41061Total
Japan5753110
08

Study locations

8 sites
  • Chubu region, Japan
  • Chugoku region, Japan
  • Hokkaido region, Japan
  • Kanto region, Japan
  • Kinki region, Japan
  • Kyushu region, Japan
  • Shikoku region, Japan
  • Tohoku region, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2007, a primary completion of Oct 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2014, 5 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2007
First posted
Apr 19, 2007
Start
Apr 2007
Primary completionActual
Oct 2008
CompletionActual
Oct 2008
Results first posted
Feb 4, 2014
Last update
Feb 4, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00462670
Responsible party
Sponsor
First posted
Apr 19, 2007
Start date
Apr 2007
Primary completion
Oct 2008
Completion
Oct 2008
Results posted
Feb 4, 2014
Last update
Feb 4, 2014

Study contacts

Katsuhisa Saito
study director · Division of New Product Evaluation and Development

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tolvaptan

Start the discussion